← Issue №14/ week of Oct 4, 2026/Esophagus/Reflux

Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Esophagus/Reflux retrospective · n=132 · Oct 1, 2026 · J Clin Gastro · IF 2.9

Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.

New evidenceesophageal motilitybasic scienceepidemiology
Clinical takeawayContinue GLP-1RA therapy in patients undergoing esophageal function testing; no evidence supports withholding GLP-1RAs due to esophageal motility concerns.
What it foundGLP-1RA use did not significantly alter esophageal motility diagnoses (P=0.07) or GERD rates (P=0.51) in patients with type 2 diabetes.
ContextConfirms prior evidence that GLP-1RAs primarily affect gastric emptying, not esophageal motility, in patients with type 2 diabetes.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wang AL … Leiman DA · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues